Compare Amphastar Pharmaceuticals Inc (AMPH) vs Canadian National Railway Co. (CNI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Canadian National Railway Co. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Canadian National Railway Co. trades at $128.11 (market cap $75.28B). The key difference: Canadian National Railway Co. is far larger — about 91.1× Amphastar Pharmaceuticals Inc's market cap, and Canadian National Railway Co. pays a 2.07% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CNI | |
|---|---|---|
Market Cap | $826.08M | $75.28B |
Sector | Health | Industrials |
52-Week High | $30.81 | $124.40 |
52-Week Low | $16.87 | $90.91 |
Enterprise Value | $1.22B | $90.74B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
CNI trades at $124.40, up 0.05% with a bullish technical outlook. The company reported Q1 2026 EPS of $1.31, meeting expectations, and maintains strong profitability with a 27.23% net margin. Recent news highlights record propane shipments and a new potash transport agreement with BHP, signaling operational strength. Analyst consensus is a Buy with a $143.71 price target, implying 15.5% upside from current levels.
The stock presents a solid long-term opportunity driven by operational efficiency and strategic growth initiatives, though elevated valuation multiples and rising debt levels warrant caution. Near-term performance hinges on Q2 2026 earnings due July 24, 2026, with market sentiment leaning positive amid sustainable dividend payments and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →
